HAMP

protein-coding

hepcidin antimicrobial peptide

Gene summary

The product encoded by this gene is involved in the maintenance of iron homeostasis, and it is necessary for the regulation of iron storage in macrophages, and for intestinal iron absorption. The preproprotein is post-translationally cleaved into mature peptides of 20, 22 and 25 amino acids, and these active peptides are rich in cysteines, which form intramolecular bonds that stabilize their beta-sheet structures. These peptides exhibit antimicrobial activity against bacteria and fungi. Mutations in this gene cause hemochromatosis type 2B, also known as juvenile hemochromatosis, a disease caused by severe iron overload that results in cardiomyopathy, cirrhosis, and endocrine failure. [provided by RefSeq, Oct 2014]

MANE transcript

NM_021175.4

Inheritance

AR

ClinVar variants

P:8U:21B:33

Top phenotype

Hemochromatosis, type 2B

gnomAD constraint

pLI —, LoF o/e 0.88

Max pathogenic AF

—

Genomic locus

chr19:35,280,716-35,285,143

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~4.4 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

hemochromatosis type 2SUPPORTIVE

Inheritance Pattern: AR

Disease ID:MONDO:0019257

Submitter: Orphanet

hemochromatosis type 2BDEFINITIVE

Inheritance Pattern: AR

Disease ID:MONDO:0013220

Submitter: ClinGen

The HAMP gene encodes hepcidin, a human antimicrobial peptide that is predominantly expressed in the liver. Hepcidin functions as a key iron-regulatory hormone, playing a central role in systemic iron homeostasis (PMIDs: 11034317, 11113131, 11113132). In 2003, HAMP was first implicated in autosomal recessive hemochromatosis type 2B (HH2B) (Roetto et al., PMID: 12469120). HH2B is characterized by elevated transferrin saturation, serum ferritin and iron levels, increased liver transaminases, and hepatic iron accumulation. Clinical manifestations include cirrhosis, liver fibrosis, hepatosplenomegaly, cardiomyopathy, hyperpigmentation, hypogonadism, diabetes, arthritis, and hematological abnormalities. A range of pathogenic variants in HAMP has been reported in affected individuals, including missense, nonsense, and frameshift mutations, as well as a recurrent 5′UTR base change. This curation includes 12 unrelated probands and 9 unique variants (PMIDs: 12469120, 14630809, 15024747, 15099344, 15198949, 16960153, 19342478, 22297252, 29085829, 33016646, 36925058). The gene-disease relationship is strongly supported by case-level evidence, exceeding the maximum score of 12 points. Additional support comes from animal models, expression, and functional studies (PMIDs: 11034317, 11113131, 11113132, 16574947, 24816174, 15933050, 27897970, 12704388). Northern blot and RT-PCR analyses of human tissues confirmed that hepcidin is predominantly expressed in the liver (PMIDs: 11034317, 11113132). Studies in mice demonstrated that hepcidin expression is upregulated in response to increased serum and hepatic iron levels. Hepcidin regulates systemic iron concentration via the hepcidin–ferroportin axis, underscoring its central role in iron homeostasis (PMIDs: 11113132, 15933050). HAMP knockout (KO) mouse models recapitulate key features of the human HH2B phenotype, including elevated hepatic iron, serum iron, and ferritin levels (PMIDs: 16574947, 24816174). KO mice fed an iron-rich diet developed elevated liver enzymes, hepatomegaly, chronic liver inflammation, liver cell apoptosis, and tissue fibrosis, suggesting that hepcidin deficiency combined with iron overload contributes to liver injury (PMID: 24816174). Furthermore, transgenic overexpression of hepcidin in HFE KO mice rescued hepatic iron accumulation, reinforcing hepcidin’s role in iron regulation (PMID: 12704388). Cardiac-specific deletion of hepcidin led to heart enlargement, increased expression of hypertrophic markers MYH7 and NPPB, and cardiomyocyte apoptosis. These KO mice exhibited reduced cardiac function and impaired activity of iron-dependent and mitochondrial enzymes, which were restored upon iron supplementation. Additionally, ferroportin expression was upregulated in KO heart tissue, consistent with the loss of hepcidin-mediated regulation. This local iron deficiency, driven by enhanced iron efflux, was reversed by treating cultured cardiomyocytes with hepcidin (PMID: 27897970). In summary, there is definitive evidence supporting the association between HAMP and autosomal recessive hemochromatosis type 2B. This relationship has been consistently demonstrated in both research and clinical diagnostic settings and has remained robust over time. This classification was approved by the ClinGen IEM GCEP at the meeting on October 10, 2025 (SOP Version 11).

hemochromatosis type 2BSTRONG

Inheritance Pattern: AR

Disease ID:MONDO:0013220

Submitter: Genomics England PanelApp

hemochromatosis type 2BSTRONG

Inheritance Pattern: AR

Disease ID:MONDO:0013220

Submitter: Labcorp Genetics (formerly Invitae)

hemochromatosis type 2BSTRONG

Inheritance Pattern: AR

Disease ID:MONDO:0013220

Submitter: PanelApp Australia

hemochromatosis type 2BDEFINITIVE

Inheritance Pattern: AR

Disease ID:MONDO:0013220

Submitter: G2P

Clinical Genomic Database (CGD)

Hemochromatosis, type 2BAR

Manifestation: Biochemical; Cardiovascular; Endocrine; Gastrointestinal; Hematologic

Intervention: Biochemical; Gastrointestinal; Hematologic

Rationale: Patients may benefit from surveillance related to iron overload, and from interventions such as venesection; Certain agents should be avoided (eg, alcohol consumption; iron-containing compounds; uncooked seafood); Hormone therapy may be beneficial in order to prevent osteoporosis

Comments: Digenic inheritance (with HFE) has been reported; HAMP variants may contribute to severity/manifestations of hemochromatosis associated with variants in other genes

Refs: 10205270; 12490283; 12915468; 12469120; 15099344; 15345104; 14670915; 15024747; 15198949; 16204153; 19214511; 20301349; 22297252; 22924847Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to HAMP variants in ClinVar

9 Conditions Cataloged
Hereditary hemochromatosisTotal: 68
Hemochromatosis type 2BTotal: 15
not providedTotal: 9
not specifiedTotal: 8
Inborn genetic diseasesTotal: 6
HAMP-related disorderTotal: 4
Hemochromatosis, juvenile, digenicTotal: 1
Hemochromatosis type 1Total: 1

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_021175.4. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
1
clinvar
31
clinvar
32
missense
1
clinvar
1
clinvar
16
clinvar
2
clinvar
20
nonsense
1
clinvar
1
clinvar
2
clinvar
4
start loss
1
clinvar
1
frameshift
2
clinvar
2
clinvar
4
splice donor/acceptor (+/-2bp)
1
clinvar
1
Total442133062

Highest pathogenic variant AF is 0.000018591001

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 9 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_021175.4RefSeqNP_066998.13MANE Select
ENST00000222304.5EnsemblENSP00000222304.23MANE Select
ENST00000598398.5EnsemblENSP00000471894.13Standard
ENST00000869748.1EnsemblENSP00000539807.12Standard

Model Organisms & Knockout Phenotypes

Observed phenotypic effects in mouse and zebrafish models

Gene / ModelOrganismObserved Phenotype
hampDanio rerio

Structure: vertebra

Quality: decreased occurrence

abnormal

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Iron metabolism in placenta
  • Hfe effect on hepcidin production

Biological Process

  • negative regulation of transcription by RNA polymerase II
  • cellular iron ion homeostasis
  • acute-phase response
  • immune response
  • aging

Molecular Function

  • hormone activity

Cellular Component

  • extracellular region
  • extracellular space
  • intercalated disc
  • apical cortex

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000598398
Coding exons
3
Length
4428
Individuals with no LoFs
125738
Homozygous LoFs
0
Heterozygous LoFs
10
Defined
125748
p
0.0000398
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense0.1514345.90.9370.00000259542
Missense (PolyPhen)713.1710.53146147
Synonymous-1.902918.61.560.00000114162
Loss of Function0.19833.390.8841.50e-732

Population LoF Frequency

PopulationCAFp-valueStatus
African0.0000620.000062rare
Latino/Admixed American00.0absent
Ashkenazi Jewish00.0absent
East Asian0.000380.00038rare
Finnish00.0absent
European (Non-Finnish)0.0000180.000018rare
South Asian00.0absent
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Liver-produced hormone that constitutes the main circulating regulator of iron absorption and distribution across tissues. Acts by promoting endocytosis and degradation of ferroportin, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma. Controls the major flows of iron into plasma: absorption of dietary iron in the intestine, recycling of iron by macrophages, which phagocytose old erythrocytes and other cells, and mobilization of stored iron from hepatocytes (PubMed:22306005). {ECO:0000269|PubMed:22306005}.;
Disease
DISEASE: Hemochromatosis 2B (HFE2B) [MIM:613313]: A juvenile form of hemochromatosis, a disorder of iron metabolism with excess deposition of iron in a variety of organs leading to their failure, bronze skin pigmentation, hepatic cirrhosis, arthropathy and diabetes. The most common symptoms of juvenile hemochromatosis at presentation are hypogonadism and cardiomyopathy. {ECO:0000269|PubMed:12915468, ECO:0000269|PubMed:14630809, ECO:0000269|PubMed:14633868, ECO:0000269|PubMed:14670915, ECO:0000269|PubMed:15099344}. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.542

Intolerance Scores

LoFtool
0.438
RVIS EVS
0.46
RVIS percentile EVS
78.16

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
N
Indispensability score
0.114

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.